This is different than the glps, directly targeting subcutaneous fat.
Link to an earlier paper on the treatment:
https://pmc.ncbi.nlm.nih.gov/articles/PMC9384315/
"At a dose of 2.0 mg/cm2, CBL-514 safely and significantly reduced abdominal fat volume by 24.96%, making it a promising new treatment for routine, nonsurgical abdominal fat reduction in dermatologic clinics."
This is different than the glps, directly targeting subcutaneous fat.
Link to an earlier paper on the treatment: https://pmc.ncbi.nlm.nih.gov/articles/PMC9384315/ "At a dose of 2.0 mg/cm2, CBL-514 safely and significantly reduced abdominal fat volume by 24.96%, making it a promising new treatment for routine, nonsurgical abdominal fat reduction in dermatologic clinics."